Rallybio to Present at Upcoming Investor Conferences in September
31 8월 2023 - 9:00PM
Business Wire
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage
biotechnology company committed to identifying and accelerating the
development of life-transforming therapies for patients with severe
and rare diseases, today announced its participation in the
following upcoming investor conferences:
- 2023 Wells Fargo Healthcare Conference in Everett, MA on
Thursday, September 7, 2023. Stephen Uden, M.D., Chief Executive
Officer, and Martin Mackay, Ph.D., Executive Chairman, will
participate in a fireside chat at 12:45 p.m. ET.
- H.C. Wainwright 25th Annual Global Investment Conference
in New York, NY on Tuesday, September 12, 2023. Dr. Uden will
participate in a panel discussion, “A New Era for Complement
Inhibitors,” at 10:00 a.m. ET.
- 2023 Cantor Global Healthcare Conference in New York, NY
on Wednesday, September 27, 2023. Dr. Uden and Dr. Mackay will
participate in a fireside chat at 4:10 p.m. ET.
Live webcasts of the Wells Fargo and Cantor fireside chats will
be accessible through the Events and Presentations section of
Rallybio’s website at www.rallybio.com. A replay of the webcasts
will be available for 30 days following each presentation.
About Rallybio Rallybio (NASDAQ: RLYB) is a
clinical-stage biotechnology company with a mission to develop and
commercialize life-transforming therapies for patients with severe
and rare diseases. Rallybio has built a broad pipeline of promising
product candidates aimed at addressing diseases with unmet medical
need in areas of maternal fetal health, complement dysregulation,
hematology, and metabolic disorders. The Company has two clinical
stage programs: RLYB212, an anti-HPA-1a antibody for the prevention
of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and
RLYB116, an inhibitor of complement component 5 (C5), with the
potential to treat several diseases of complement dysregulation, as
well as additional programs in preclinical development.
Rallybio is headquartered in New Haven, Connecticut with an
additional facility at the University of Connecticut’s Technology
Incubation Program in Farmington, Connecticut. For more
information, please visit www.rallybio.com and follow us on
LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230824296440/en/
Investors Ami Bavishi Head of Investor Relations and
Communications 475-47-RALLY (Ext. 282) abavishi@rallybio.com
Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Media Jorge Gaeta Mission North (516) 430-7659
Rallybio@missionnorth.com
Rallybio (NASDAQ:RLYB)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Rallybio (NASDAQ:RLYB)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024